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Reply to Pragliola et al.
To the Editor:
In their letter to the editor, Pragliola et al. (1997 [in this
issue]) have noted that in our manuscript (Gottlieb et
al. 1997) we assume that the GSCL gene is deleted in
patient G (Levy et al. 1995), a patient with DiGeorge
syndrome who has an atypical deletion boundary in
chromosome 22. Their FISH analysis indicates that
GSCL in fact is not deleted in this patient. Since patient
G was unavailable to us for analysis, we were unable to
verify the deletion status of GSCL. We based our esti-
mate of the deletion boundary in patient G on the in-
formation provided in a previous paper published by the
same senior investigator (Rizzu et al. 1996): in an article
by Rizzu et al. (1996), the deletion endpoint of patient
G is described as 100–150 kb telomeric to the ADU/
VDU breakpoint, “close to the 5′ end” of theDGSI/ES2
gene. Since we had the complete sequence of the ∼120-
kb region extending from the ADU breakpoint toGSCL,
and since we knew that the 5′ end of GSCL is ∼6 kb
fromDGSI/ES2,we felt that it was reasonable to assume
thatGSCLwas disrupted or deleted in this patient. Prag-
liola et al. indicate in their letter that, although the de-
letion endpoint in patient G is within a fosmid contain-
ing GSCL, the breakpoint is distal to the 5′ end of the
gene. However, as they note—and as we pointed out in
our paper—a deletion or translocation breakpoint can
easily affect the expression of genes in the vicinity. There-
fore, the expression of GSCL could still be affected in
patient G. Moreover, as we stated in our paper, the def-
inition of a minimal critical region does not exclude a
role for genes outside the region. Thus, although we
consider GSCL to be a strong candidate gene for some
of the abnormalities associated with DiGeorge syn-
drome/velocardiofacial syndrome, we have not excluded
the possibility that genes outside the regions that we have
called the “DiGeorge minimal critical region,” or the
smallest region of deletion, play a role in the disease
phenotype. We appreciate the additional data from Prag-
liola et al., clarifying the location of the proximal break-
point in patient G.
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Table 1
MTHFR Genotype in Healthy Japanese Stratified by Age Groups and Gender
YOUNGER (!55 YEARS) OLDER (55–79 YEARS) OLDEST (x80 YEARS)
n
MTHFR Allelea
n
MTHFR Allelea
n
MTHFR Allelea
/ / or / / / or / / / or /
Maleb 147 .21 .79 227 .15 .85 79 .08 .92
Female 164 .17 .83 259 .13 .87 69 .07 .93
Totalc 311 .19 .81 486 .14 .86 148 .07 .93
a A plus sign () denotes the mutant allele; and a minus sign () denotes the wild-type allele.
b , , for differences among the three age groups.2x  7.25 P  .027
c , , for differences among the three age groups.2x  10.39 P  .006
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The Frequency of the Methylenetetrahydrofolate
Reductase–Gene Mutation Varies with Age in the
Normal Population
To the Editor:
Cardiovascular disease and cerebrovascular disease are
second only to cancer as the leading causes of death in
Japan, and their mortality rates rise with the age of the
population (Health and Welfare Statistics Association
1995). In addition to environmental factors such as
smoking, genetic factors are involved in determining an
individual’s susceptibility to vascular disease. Because
low frequency of genetic risk factors for vascular disease
could contribute to a population’s longevity, the fre-
quency of potentially protective genotypesmay be higher
in the oldest segment of the population.
For the past decade, mild hyperhomocysteinemia has
been recognized as a risk factor for occlusive arterial
disease and thrombosis. Methylenetetrahydrofolate re-
ductase (MTHFR) is the key enzyme in the methylation
of homocysteine. A homozygous mutation of the
MTHFR gene (677CrT; ArV) alters a highly conserved
amino acid, resulting in decreased specific MTHFR ac-
tivity and elevated levels of homocysteine (Frosst et al.
1995). According to a recent report on patients with
premature vascular disease, this mutation is associated
with a threefold increase in risk for premature cardio-
vascular disease (Kluijtmans et al. 1996).
Individuals with the homozygous 677CrT mutation
have been reported to show increased thermolability of
MTHFR (Frosst et al. 1995). One study attributed the
abnormal homocysteine metabolism in 28% of the ho-
mocysteinemic patients with premature vascular disease
to thermolabile MTHFR (Engbersen et al. 1995). An-
other study indicated that an association between the
thermolabile MTHFR defect and coronary artery disease
is independent of other known risk factors for coronary
artery disease (Kang et al. 1993).
These observations led us to speculate that the
MTHFR mutation may be partly responsible for car-
diovascular disease, thus decreasing the probability of
an individual’s reaching old age. To test this hypothesis,
we investigated the frequency of the MTHFR mutation
in 945 unrelated, healthy subjects 14–99 years old, all
Japanese living in a single local area. Information about
health condition (e.g., history of hypertension, hyperlip-
idemia, diabetes mellitus, stroke, and heart disease) was
obtained by semistructured interview of 506 subjects
who were 160 years old. We assessed blood pressure at
rest twice during the interview.
Taking account of the rising rate of mortality due to
cardiovascular and cerebrovascular diseases in people
180 years old, we stratified the subjects into three age
groups: younger (X54 years; ), older (55–79n  311
years; ), and oldest (x80 years; , ofn  486 n  148
whom 22 were x90 years of age). DNA was extracted
from peripheral leukocytes obtained from each subject,
and MTHFR genotyping was performed as described by
Frosst et al. (1995).
As shown in table 1, the MTHFR mutation decreased
as the ages of the subjects increased. The homozygous
MTHFR mutation occurred in 19% of the younger
group and in 14% of the older group, whereas we found
the mutation in only 7% of the oldest group. The ho-
mozygous mutation occurred significantly less often in
both the older and oldest groups than in the younger
group, especially among males (total— , 2df  2 x 
, ; males— , , ;210.39 P  .006 df  2 x  7.25 P  .027
females— , , ). The MTHFR-2df  2 x  3.59 P  .166
genotype distributions for the younger and older age
groups were in Hardy-Weinberg equilibrium, but the dis-
tribution for octogenarians and nonagenarians was not
